EMEA-001220-PIP01-11-M06 - paediatric investigation plan
Baricitinib
PIPHuman
Eli Lilly & Company Limited
Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com
P/0004/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M06)